Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
I. Zakharenkov (Bryansk, Russian Federation), S. Rachina (Moscow, Russian Federation), R. Kozlov (Smolensk, Russian Federation), A. Sinopalnikov (Moscow, Russian Federation), S. Yatsyshina (Moscow, Russian Federation), N. Ivanchik (Smolensk, Russian Federation), N. Dechnich (Smolensk, Russian Federation), Y. Yanovich (Moscow, Russian Federation), S. Gordeeva (Murmansk, Russian Federation), U. Portnyagina (Yakutsk, Russian Federation), M. Lebedeva (Novosibirsk, Russian Federation), M. Archipenko (Krasnodar, Russian Federation). Etiology and antibiotic resistance patterns in adults with severe community-acquired pneumonia in Russia. 2909

Member's Comments

No comment yet.

Related content which might interest you: Etiology of severe community-acquired pneumonia in Japan Source: Eur Respir J 2005; 26: Suppl. 49, 256s Year: 2005 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Particularities of community-acquired pneumonia in the elderly Source: Annual Congress 2007 - Miscellaneous lower respiratory tract infections Year: 2007 Peculiarities of community-acquired pneumonia in tobacco-smoking patients Source: Annual Congress 2009 - Tobacco: from smoke to disease Year: 2009 Antibiotic management of nosocomial pneumonia in children Source: Eur Respir J 2006; 28: Suppl. 50, 633s Year: 2006 Severe community-acquired pneumonia in China: epidemiology and clinical practice Source: International Congress 2019 – Chinese programme 2019: Part II Year: 2019 Lower respiratory tract infections: when are antibiotics mandatory? Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=146 Year: 2004 Severe community-acquired pneumonia Source: Eur Respir Monogr 2016; 74: 101-116 Year: 2016 Evolution of antimicrobial resistance trends in the last five years in patients with bacteremic Pneumococcal community-acquired pneumonia (CAP-SP) Source: Eur Respir J 2005; 26: Suppl. 49, 639s Year: 2005 Etiology of community-acquired pneumonia (CAP) in young hospital patients Source: Eur Respir J 2002; 20: Suppl. 38, 356s Year: 2002 Etiological spectrum of hospitalized community-acquired pneumonia Source: Annual Congress 2007 - Pulmonary infections in the immunocompetent and immunocompromised host Year: 2007 Epidemiology of community-acquired pneumonia and nosocomial pneumonia Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Etiology and clinical outcome of community-acquired pneumonias in hospitalized children Source: Eur Respir J 2007; 30: Suppl. 51, 398s Year: 2007 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Community-acquired pneumonia: severity and antibiotic treatments Source: ERS Course 2018 - Respiratory Infections Year: 2018 Antibiotics and new guidelines for the treatment of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=175 Year: 2004 Prevalence of atypical bacterial pathogens in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020